Promising cancer drug study halted early – what we know
Disease control
Terminated
This study tested a drug called Promitil in people with ovarian or pancreatic cancer that has specific gene mutations (BRCA or HRD) and has worsened after first treatment. The goal was to see if the drug could slow cancer growth and be safe. The study was stopped early, so result…
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated May 10, 2026 20:04 UTC